课题基金 / 基金详情

Manipulating immunity to Mycobacterium tuberculosis with novel vaccines and immunotherapeutics

Manipulating immunity to Mycobacterium tuberculosis with novel vaccines and immunotherapeutics
用新型疫苗和免疫疗法控制结核分枝杆菌的免疫力
批准号:
nhmrc : 402728
负责人:
A/Pr James Triccas
金额:
$34.99万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2006
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2006-01-01 至 2008-12-31

项目摘要

项目成果

A/Pr James Triccas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Tuberculosis (TB) is an enormous world health problem with 2 million deaths per year and an estimated one third of the world s population infected with the TB bacterium. People who become infected with the bacterium and cannot clear the infection are at great risk of developing TB later in life. Control of TB is confronted with two major problems. First, the only vaccine available for TB, known as BCG, is not very effective at preventing the disease. We do not know why BCG is not an effective vaccine and the type of immune response required to achieve optimal protection against TB is not fully understood. Second, the drugs currently used to treat TB are expensive, treatment times are long and drug resistance is increasing at an alarming rate. Therefore there is an urgent need to develop new vaccines and therapies against TB. We propose to use animal models of TB infection and sophisticated immunological techniques to compare immune responses generated by TB, BCG and new generation vaccines developed in our laboratory. This will allow us to identify the key features of a vaccine that results in effective, long-lasting protection against TB infection. Novel strategies to increase the immune response in the lung, the main site of TB infection, will also be examined. This will involve pulmonary delivery of molecules that increase the number and effectiveness of lung antigen presenting cells, which are necessary to drive the right type of immune response to eradicate the TB bacterium. Increasing lung immunity will be used to either boost the effect of the BCG vaccine, or as a therapy to kill the bacterium in those already infected. This is an internationally competitive project and our team is at the forefront of this research effort. The development of new vaccines to prevent TB or new strategies to treat established TB infection would be a major medical breakthrough and a represent a significant achievement for Australian health and medical research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multistage vaccines for the prevention of tuberculosis
  • 批准号:
    nhmrc : 1102597
  • 项目类别:
    Project Grants
  • 资助金额:
    $60.84万
  • 财政年份:
    2016
  • 负责人:
    A/Pr James Triccas
  • 依托单位:
A new class of inhibitors for the treatment of tuberculosis
  • 批准号:
    nhmrc : 1084266
  • 项目类别:
    Project Grants
  • 资助金额:
    $48.06万
  • 财政年份:
    2015
  • 负责人:
    A/Pr James Triccas
  • 依托单位:
New candidate vaccines to prevent tuberculosis: preclinical assessment of efficacy, safety and mechanism of protection
  • 批准号:
    nhmrc : 1043519
  • 项目类别:
    Project Grants
  • 资助金额:
    $39.62万
  • 财政年份:
    2013
  • 负责人:
    A/Pr James Triccas
  • 依托单位:
Genes of Mycobacterium tuberculosis essential for Latent Tuberculosis Infection
  • 批准号:
    nhmrc : 1051246
  • 项目类别:
    Project Grants
  • 资助金额:
    $39.35万
  • 财政年份:
    2013
  • 负责人:
    A/Pr James Triccas
  • 依托单位:
国内基金
海外基金
SENP5调控磷酸化STAT2的SUMO修饰促进抗病毒天然免疫的机制研 究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    胡源
  • 依托单位:
外周犬尿氨酸通过脑膜免疫致海马BDNF水平降低介导术后认知功能障碍
  • 批准号:
    82371193
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    苏殿三
  • 依托单位:
microRNA对机体抗病毒固有免疫应答RIG-I信号途径的调控作用及机制研究
C型凝集素样受体识别在原发性皮肤毛霉病中的作用
  • 批准号:
    81171510
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2011
  • 负责人:
    李若瑜
  • 依托单位: